Key result
Review outlines indications, technique, and clinical outcomes of WATCHMAN LAA closure in AFib.
Why the study?
Oral anticoagulation reduces thromboembolism in AF but carries risks of relevant bleeding, interactions, and noncompliance, making left atrial appendage closure an alternative for patients with contraindications.
This review summarizes the rationale, indications, technical aspects, and clinical results of left atrial appendage closure using the WATCHMAN device for stroke prevention in AF patients contraindicated for oral anticoagulation.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. The most feared complication of AF is thromboembolism. Oral anticoagulation (OAC) is the standard treatment to reduce thromboembolism occurrence in patients with AF. The rate of relevant bleeding, medical interactions and incompliance under OAC remains consistent. In this context, patients with AF at high risk for thromboembolism and with a contraindication to OAC may be considered as candidates for percutaneous left atrial appendage closure. In this review, we discuss the rationale, indications, technical aspects and clinical results of left atrial appendage closure by means of the WATCHMAN® (Boston Scientific, MA, USA) device.
No takes yet. Share an insight, caveat, or question.
D’Ancona et al. (2020) conducted a review in Atrial fibrillation. Percutaneous left atrial appendage closure (WATCHMAN device) was evaluated. This review discusses the rationale, indications, technical aspects, and clinical results of percutaneous left atrial appendage closure using the WATCHMAN device for patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: